Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension

Current Hypertension Reports

Volumn 14, Issue 4, 2012, Pages 304-309

  Sudano, Isabella ^a   Flammer, Andreas J ^a,b   Roas, Susanne ^a   Enseleit, Frank ^a   Noll, Georg ^a,c   Ruschitzka, Frank ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Acetaminophen; Antihypertensive agents; Cardiovascular risk; COX inhibitors; Nonsteroidal antiinflammatory drugs; Pain relieving therapy

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB;

ADENOMATOUS POLYP; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTRACARDIAC THROMBOSIS; LOW DRUG DOSE; NONHUMAN; OSTEOARTHRITIS; PAIN; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR;

ACETAMINOPHEN; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PRESSURE; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; HYPERTENSION; PAIN; RISK;

EID: 84865656453     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0274-7     Document Type: Article

References (47)

1. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286 (8):954-9. (Pubitemid 33010342)
2. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ. 2005;330(7504):1366.
3. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: Nested case-control analysis. BMJ. 2005;330(7499):1059-63. (Pubitemid 40646559)
4. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation. 2007;115:1634-142.
5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective C. Studies, Age-specific relevance of usual blood pressure to vascular mortality: A meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360 (9349):1903-13. (Pubitemid 35472129)
6. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: Meta-Analysis of outcome trials. Lancet. 2011;378(9789):380-2.
7. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B. C. Blood Pressure Lowering Treatment Trialists, The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: Meta-Analysis of randomized trials. J Hypertens. 2011;29(1):4-16. Metaanalysis evaluating the link between increase/reduction in blood pressure and major cardiovascular events.
8. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-Analysis. Ann Intern Med. 1994;121(4):289-300.
9. Pope JE, Anderson JJ, Felson DT. A meta-Analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477-84. (Pubitemid 23064991)
10. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98(3):266-74.
11. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633-44. (Pubitemid 44511610)
12. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-Analysis of randomised trials. BMJ. 2006;332(7553):1302-8.
13. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.
14. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, Garcia-Rodriguez LA. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155-63.
15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, V.S. Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520-8. 2 p following 1528.
16. Messerli FH, Sichrovsky T. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Am J Cardiol. 2005;96(6):872-3. (Pubitemid 41317668)
17. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: Final analysis of the APPROVe trial. Lancet. 2008;372 (9651):1756-64.
18. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma I. Prevention with Celecoxib Study. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-80. (Pubitemid 40365348)
19. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N,Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114(10):1028-35. (Pubitemid 44358879)
20. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials, 2006. 1(7): P. e33.
21. Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27 (4):886-93.
22. Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Luscher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, Graham DY, Yeomans ND, Krum H, Ruschitzka F, Lincoff AM, Nissen SE. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157(4):606-12. A new study which results could help us choosing a correct treatment for patients with arthritis which may reduce pain without increasing cardiovascular risk.
23. The Standard Care versus Celecoxib Outcome Trial (SCOTLSSS). . 2007.
24. Krum H, Aw TJ, Liew D, Haas S. Blood pressure effects of COX-2 inhibitors. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S43-8. (Pubitemid 44651784)
25. Krum, H., G. Swergold, A. Gammaitoni, P.M. Peloso, S.S. Smugar, S.P. Curtis, D.C. Brater, H. Wang, A. Kaur, L. Laine, M.R. Weir, and C.P. Cannon, Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther, 2011. Review aiming to evaluate the link between blood pressure increase and cardiovascular risk in patients taking nonsteroidal antiinflammatory drugs.
26. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) programme: A randomised comparison. Lancet. 2006;368(9549):1771-81. (Pubitemid 44739003)
27. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib E. Rofecoxib, and I. Safety in Comorbidities Evaluation Trial, The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(2):161-8.
28. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol. 2003;42(10):1747-53. (Pubitemid 37433652)
29. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107(3):405-9.
30. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in saltinduced hypertension. Circulation. 2003;108(19):2308-11. (Pubitemid 37413534)
31. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney Jr. JF, Morrow JD, Vita JA. Short-And long-Term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42(3):310-5. (Pubitemid 37093478)
32. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E,Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, Group TS. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364(9435):675-84. (Pubitemid 39140623)
33. Guazzi MD, Campodonico J, Celeste F, Guazzi M, Santambrogio G, Rossi M, Trabattoni D, Alimento M. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther. 1998;63(1):79-86. (Pubitemid 28070188)
34. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet. 1998;351(9118):1755-62. (Pubitemid 28269185)
35. Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I, Wedel H, Group HOTS. Benefit and harm of low-dose aspirin in well-Treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002;20(11):2301-7. (Pubitemid 35388250)
36. Zanchetti A, Hansson L, Leonetti G, RahnKH, Ruilope L,Warnold I, Wedel H. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens. 2002;20(5):1015-22. (Pubitemid 34913684)
37. Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M,Wolfrum M, Hirt A, Kaiser P, Hurlimann D, NeidhartM, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Luscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122(18):1789-96. First study in which the effect of chronic therapy with paracetamol on blood pressure and endothelial function in patients with coronary artery disease was prospectively assessed in a cross-over double blind placebo controlled manner.
38. Chalmers JP, West MJ, Wing LM, Bune AJ, Graham Jr. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A. 1984;6 (6):1077-93. (Pubitemid 14083631)
39. Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: A controlled trial. Can J Clin Pharmacol. 2008;15(3):e372-82.
40. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, doubleblind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987;107(5):628-35. (Pubitemid 18041856)
41. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46(3):500-7. (Pubitemid 41376829)
42. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167 (4):394-9. (Pubitemid 46333941)
43. White WB, Campbell P. Blood pressure destabilization on nonsteroidal antiinflammatory agents: Acetaminophen exposed? Circulation. 2010;122(18):1779-81.
44. Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther. 2005;12(1):46-55. (Pubitemid 40516046)
45. Mattammal MB, Zenser TV, Brown WW, Herman CA, Davis BB. Mechanism of inhibition of renal prostaglandin production by acetaminophen. J Pharmacol Exp Ther. 1979;210(3):405-9. (Pubitemid 10226345)
46. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22 (2):383-90. (Pubitemid 351225574)
47. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: New vistas of an old drug. CNS Drug Rev. 2006;12 (3-4):250-75. (Pubitemid 46047791)